Ogivri 150 MG Injection

RxCUI: 2179758
RxNorm name: Ogivri 150 MG Injection
Display name: Ogivri 150 MG Injection
Full name: Ogivri 150 MG Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:02

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761074	Ogivri	trastuzumab-dkst	351(k) Biosimilar	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
OGIVRI	TRASTUZUMAB-DKST	Biocon Biologics Inc.	b6465b44-a6dd-f99c-d009-6851cf05169c	2024-11-30	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2179758

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
6b7938e6-14c7-4a65-9605-967542ecfb8f	OGIVRI 150 MG Injection [PSN] · trastuzumab-dkst 150 MG Injection [Ogivri] [SBD] · Ogivri 150 MG Injection [SY]	3	15	These highlights do not include all the information needed to use OGIVRI safely and effectively. See full prescribing information for OGIVRI . OGIVRI ® (trastuzumab-dkst) for injection, for intravenous use Initial U.S. Approval: 2017 OGIVRI ® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).	20210208
b6465b44-a6dd-f99c-d009-6851cf05169c	OGIVRI 150 MG Injection [PSN] · trastuzumab-dkst 150 MG Injection [Ogivri] [SBD] · Ogivri 150 MG Injection [SY]	3	14	These highlights do not include all the information needed to use OGIVRI safely and effectively. See full prescribing information for OGIVRI . OGIVRI ® (trastuzumab-dkst) for injection, for intravenous use Initial U.S. Approval: 2017 OGIVRI ® (trastuzumab-dkst) is biosimilar* to HERCEPTIN (trastuzumab).	20241130